Peptide Source Tracker

Prime Peptides Review

primepeptides.co

Active — FDA warning letterSince 2024-12-10

Peptide Source Tracker is independent and not affiliated with Prime Peptides.

Prime Peptides is operating; it has unconfirmed testing and documentation inputs, and has unconfirmed payment methods. The FDA sent Prime Peptides a warning letter in December 2024 alleging unapproved-new-drug claims involving semaglutide and retatrutide. A warning letter is an allegation of violations, not a finding of guilt.

Published rubric

Scorecard

Documentationunknownunverified1.5/3
Testingunknownunverified1.5/3
Payment safetyunknownunverified1.5/3
Track recordagency warning letter1/3
Total score4.6†out of 10

Documented history

Record

FDA warning letter alleging unapproved-new-drug claims involving semaglutide and retatrutide

FDA Warning Letter 695156 alleged that Prime Vitality, Inc. dba Prime Peptides marketed semaglutide and retatrutide as unapproved new drugs for human use despite research-use-only labeling.

Sources

Facts

Domainprimepeptides.co
StatusActive — FDA warning letter
Last verified
Testingreported by Finnrick and Peptide Examiner, unverified: Janoshik verification records and Freedom Diagnostics testing
PaymentsPayment methods unconfirmed

From the operator

Compare against a fully documented vendor
Curo publishes a verifiable COA for every lot and takes card payment — see the documentation standard this tracker scores against.
See Curo's COAs

Related reviews

Swiss ChemsPure RawzUmbrella Labs
Compare all vendors →